Ahn Young-Ho, Ko Yoon Ho
Department of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Korea.
Inflammation-Cancer Microenvironment Research Center, College of Medicine, Ewha Womans University, Seoul 07804, Korea.
Int J Mol Sci. 2020 Nov 20;21(22):8782. doi: 10.3390/ijms21228782.
microRNAs (miRNAs), endogenous suppressors of target mRNAs, are deeply involved in every step of non-small cell lung cancer (NSCLC) development, from tumor initiation to progression and metastasis. They play roles in cell proliferation, apoptosis, angiogenesis, epithelial-to-mesenchymal transition, migration, invasion, and metastatic colonization, as well as immunosuppression. Due to their versatility, numerous attempts have been made to use miRNAs for clinical applications. miRNAs can be used as cancer subtype classifiers, diagnostic markers, drug-response predictors, prognostic markers, and therapeutic targets in NSCLC. Many challenges remain ahead of their actual clinical application; however, when achieved, the use of miRNAs in the clinic is expected to enable great progress in the diagnosis and treatment of patients with NSCLC.
微小RNA(miRNA)作为靶mRNA的内源性抑制因子,深度参与非小细胞肺癌(NSCLC)发展的各个阶段,从肿瘤起始到进展及转移。它们在细胞增殖、凋亡、血管生成、上皮-间质转化、迁移、侵袭、转移定植以及免疫抑制中发挥作用。由于其多功能性,人们已多次尝试将miRNA用于临床应用。miRNA可作为NSCLC的癌症亚型分类器、诊断标志物、药物反应预测指标、预后标志物及治疗靶点。在其实际临床应用之前仍存在许多挑战;然而,一旦实现,miRNA在临床上的应用有望在NSCLC患者的诊断和治疗方面取得巨大进展。